(+)-MatairesinolCAS# 148409-36-3 |
- Matairesinol
Catalog No.:BCN5789
CAS No.:580-72-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 148409-36-3 | SDF | Download SDF |
| PubChem ID | 11451194 | Appearance | Powder |
| Formula | C20H22O6 | M.Wt | 358.39 |
| Type of Compound | Lignans | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,4S)-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one | ||
| SMILES | COC1=C(C=CC(=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)O | ||
| Standard InChIKey | MATGKVZWFZHCLI-CABCVRRESA-N | ||
| Standard InChI | InChI=1S/C20H22O6/c1-24-18-9-12(3-5-16(18)21)7-14-11-26-20(23)15(14)8-13-4-6-17(22)19(10-13)25-2/h3-6,9-10,14-15,21-22H,7-8,11H2,1-2H3/t14-,15+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. (+)-Matairesinol shows inhibition of the discoloration of yellowtail dark muscle. 2. (+)-Matairesinol exhibits immunomodulatory activity. |
| Targets | Akt | Immunology & Inflammation related |
(+)-Matairesinol Dilution Calculator
(+)-Matairesinol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7903 mL | 13.9513 mL | 27.9026 mL | 55.8051 mL | 69.7564 mL |
| 5 mM | 0.5581 mL | 2.7903 mL | 5.5805 mL | 11.161 mL | 13.9513 mL |
| 10 mM | 0.279 mL | 1.3951 mL | 2.7903 mL | 5.5805 mL | 6.9756 mL |
| 50 mM | 0.0558 mL | 0.279 mL | 0.5581 mL | 1.1161 mL | 1.3951 mL |
| 100 mM | 0.0279 mL | 0.1395 mL | 0.279 mL | 0.5581 mL | 0.6976 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Docetaxel Trihydrate
Catalog No.:BCC1535
CAS No.:148408-66-6
- Secoisolariciresinol Diglucoside
Catalog No.:BCN1212
CAS No.:148244-82-0
- H-Dap-OH.HCl
Catalog No.:BCC3186
CAS No.:1482-97-9
- UNC 0642
Catalog No.:BCC8014
CAS No.:1481677-78-4
- (±)-Epibatidine
Catalog No.:BCC6750
CAS No.:148152-66-3
- trans-2-Tridecene-1,13-dioic acid
Catalog No.:BCN3667
CAS No.:14811-82-6
- Ac-Lys(Fmoc)-OH
Catalog No.:BCC2679
CAS No.:148101-51-3
- Fmoc-Lys(Dnp)-OH
Catalog No.:BCC3519
CAS No.:148083-64-1
- Talc
Catalog No.:BCC4730
CAS No.:14807-96-6
- Calcineurin Autoinhibitory Peptide
Catalog No.:BCC2456
CAS No.:148067-21-4
- 25-Hydroxycycloart-23-en-3-one
Catalog No.:BCN1657
CAS No.:148044-47-7
- 1-(3-(1-Hydroxy-3-methylbutyl)-4-methoxyphenyl)ethan-1-one
Catalog No.:BCN7493
CAS No.:148044-44-4
- Prion Protein 106-126 (human)
Catalog No.:BCC6027
CAS No.:148439-49-0
- L-732,138
Catalog No.:BCC6821
CAS No.:148451-96-1
- JMV 390-1
Catalog No.:BCC5922
CAS No.:148473-36-3
- MNS
Catalog No.:BCC3943
CAS No.:1485-00-3
- GRK2i
Catalog No.:BCC6048
CAS No.:148505-03-7
- Pregabalin
Catalog No.:BCN2175
CAS No.:148553-50-8
- 3,5-Dihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1658
CAS No.:14858-07-2
- 3-O-Methylquercetin tetraacetate
Catalog No.:BCN1659
CAS No.:1486-69-7
- 3-O-Methylquercetin
Catalog No.:BCN1660
CAS No.:1486-70-0
- Fmoc-Prolinol
Catalog No.:BCC2710
CAS No.:148625-77-8
- GR 127935 hydrochloride
Catalog No.:BCC7081
CAS No.:148642-42-6
- L-733,060 hydrochloride
Catalog No.:BCC5707
CAS No.:148687-76-7
New biflavanones and bioactive compounds from Stellera chamaejasme L.[Pubmed:12580104]
Yao Xue Xue Bao. 2001 Sep;36(9):669-71.
AIM: To study the chemical constituents of the root of Stellera chamaejasme L. METHODS: Various column chromatographies on silica gel and RP-18 were employed for isolation and purification. Structures of compounds were elucidated by spectral analysis. RESULTS: Eight lignans and three biflavonoids possessing a C-3/C-3" linkage were isolated. They are ruixianglangdusu A (1) and B (2), 4',4'",5,5",7,7"-hexahydroxy-3,3"-biflavone (3), (+)-kusunokinin (4), lirioresinol-B (5), magnolenin C (6), (-)-pinoresinol monomethyl ether (7), (-)-pinoresinol (8), (+)-Matairesinol (9), isohinokinin (10) and (-)-eudesmin (11). CONCLUSION: Compounds 1 and 2 are new biflavanones, 1 is enantiomeric to known chamaejasmenin C, 4, 6, 8, 9, 10 and 11 were isolated from this plant for the first time, and 7 was isolated from natural resources for the first time. In vitro bioassays showed that 3 and 8 exhibited antibacterial activity, and 1, 2, 9 and 11 exhibited immunomodulatory activity.
Inhibition of the discoloration of yellowtail dark muscle by lignan.[Pubmed:19661688]
Biosci Biotechnol Biochem. 2009 Aug;73(8):1718-21.
The inhibitory effect of (-)-, (+)-Matairesinol and (-)-, (+)-secoisolariciresinol on the discoloration of dark muscle (chiai in Japanese) of two-year-old yellowtail (hamachi in Japanese) was evaluated by measuring the X and a(*) values. (-)-Matairesinol was most effective for retaining the red color of dark muscle in this experiment.
Antiausterity activity of arctigenin enantiomers: importance of (2R,3R)-absolute configuration.[Pubmed:24660468]
Nat Prod Commun. 2014 Jan;9(1):79-82.
From a MeOH extract of powdered roots of Wikstroemia indica, six dibenzyl-gamma-butyrolactone-type lignans with (2S,3S)-absolute configuration [(+)-arctigenin (1), (+)-Matairesinol (2), (+)-trachelogenin (3), (+)-nortrachelogenin (4), (+)-hinokinin (5), and (+)-kusunokinin (6)] were isolated, whereas three dibenzyl-gamma-butyrolactone-type lignans with (2R,3R)-absolute configuration [(-)-arctigenin (1*), (-)-matairesinol (2*), (-)-trachelogenin (3*)] were isolated from Trachelospermum asiaticum. The in vitro preferential cytotoxic activity of the nine compounds was evaluated against human pancreatic PANC-1 cancer cells in nutrient-deprived medium (NDM), but none of the six lignans (1-6) with (2S,3S)-absolute configuration showed preferential cytotoxicity. On the other hand, three lignans (1*-3*) with (2R,3R)-absolute configuration exhibited preferential cytotoxicity in a concentration-dependent manner with PC50 values of 0.54, 6.82, and 5.85 microM, respectively. Furthermore, the effect of (-)- and (+)-arctigenin was evaluated against the activation of Akt, which is a key process in the tolerance to nutrition starvation. Interestingly, only (-)-arctigenin (1*) strongly suppressed the activation of Akt. These results indicate that the (2R,3R)-absolute configuration of (-)-enantiomers should be required for the preferential cytotoxicity through the inhibition of Akt activation.
